专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009108637A1 DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS 审中-公开
标题翻译：使用基于抗体的阵列进行乳腺癌治疗的药物选择
公开(公告)号：WO2009108637A1
公开(公告)日：2009-09-03
申请号：PCT/US2009/035013
申请日：2009-02-24
申请人： PROMETHEUS LABORATORIES, INC. , SINGH, Sharat , HARVEY, Jeanne , KIM, Phillip , LIU, Xinjun , LIU, Limin , BARHAM, Robert , NERI, Bruce
发明人： SINGH, Sharat , HARVEY, Jeanne , KIM, Phillip , LIU, Xinjun , LIU, Limin , BARHAM, Robert , NERI, Bruce
IPC分类号： G01N33/50
CPC分类号： G01N33/57415 , G01N33/5011 , G01N2800/52 , G01N2800/60
摘要： The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
摘要翻译：本发明提供用于检测肿瘤细胞中信号转导途径的组分的激活状态的组合物和方法。关于使用本发明的信号转导途径的组分的激活状态的信息可用于癌症诊断，预后和癌症治疗的设计。

2. 发明申请

WO2007109571A3 METHODS OF PREDICTING AND MONITORING TYROSINE KINASE INHIBITOR THERAPY 审中-公开
公开(公告)号：WO2007109571A3
公开(公告)日：2007-09-27
申请号：PCT/US2007/064217
申请日：2007-03-16
申请人： PROMETHEUS LABORATORIES, INC. , HARVEY, Jeanne , NERI, Bruce , SINGH, Sharat
发明人： HARVEY, Jeanne , NERI, Bruce , SINGH, Sharat
IPC分类号： G06F19/00 , C12Q1/68
摘要： The present invention provides methods for analyzing a combination of biomarkers to individualize tyrosine kinase inhibitor therapy in patients who have been diagnosed with cancer. In particular, the assay methods of the present invention are useful for predicting, identifying, or monitoring the response of a tumor, tumor cell, or patient to treatment with a tyrosine kinase inhibitor using an algorithm based upon biomarker profiling. The assay methods of the present invention are also useful for predicting whether a patient has a risk of developing toxicity or resistance to treatment with a tyrosine kinase inhibitor. In addition, the assay methods of the present invention are useful for monitoring tyrosine kinase inhibitor therapy in a patient receiving the drug to evaluate whether the patient will develop resistance to the drug. Furthermore, the assay methods of the present invention are useful for optimizing the dose of a tyrosine kinase inhibitor in a patient receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects.

3. 发明申请

WO2009012140A2 DRUG SELECTION FOR LUNG CANCER THERAPY USING ANTIBODY-BASED ARRAYS 审中-公开
标题翻译：使用基于抗体的阵列进行肺癌治疗的药物选择
公开(公告)号：WO2009012140A2
公开(公告)日：2009-01-22
申请号：PCT/US2008/069764
申请日：2008-07-11
申请人： PROMETHEUS LABORATORIES, INC. , SINGH, Sharat , HARVEY, Jeanne
发明人： SINGH, Sharat , HARVEY, Jeanne
IPC分类号： G01N33/574 , C12N5/08 , C12Q1/00
CPC分类号： G01N33/57423 , G01N33/5041 , G01N33/5044 , G01N33/5082 , G01N2500/10 , G01N2800/52
摘要： The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
摘要翻译：本发明提供用于检测肿瘤细胞中信号转导途径的组分的激活状态的组合物和方法。关于使用本发明的信号转导途径的组分的激活状态的信息可用于癌症诊断，预后和癌症治疗的设计。

4. 发明申请

WO2007109571A2 METHODS OF PREDICTING AND MONITORING TYROSINE KINASE INHIBITOR THERAPY 审中-公开
标题翻译：预测和监测酪氨酸激酶抑制剂治疗的方法
公开(公告)号：WO2007109571A2
公开(公告)日：2007-09-27
申请号：PCT/US2007064217
申请日：2007-03-16
申请人： PROMETHEUS LAB INC , HARVEY JEANNE , NERI BRUCE , SINGH SHARAT
发明人： HARVEY JEANNE , NERI BRUCE , SINGH SHARAT
IPC分类号： C12Q1/68 , G06F19/18 , G06F19/24
CPC分类号： G06F19/18 , C12Q1/6886 , C12Q2600/106 , C12Q2600/154 , G01N33/57484 , G01N2333/91215 , G01N2500/04 , G01N2800/52 , G06F19/24
摘要： The present invention provides methods for analyzing a combination of biomarkers to individualize tyrosine kinase inhibitor therapy in patients who have been diagnosed with cancer. In particular, the assay methods of the present invention are useful for predicting, identifying, or monitoring the response of a tumor, tumor cell, or patient to treatment with a tyrosine kinase inhibitor using an algorithm based upon biomarker profiling. The assay methods of the present invention are also useful for predicting whether a patient has a risk of developing toxicity or resistance to treatment with a tyrosine kinase inhibitor. In addition, the assay methods of the present invention are useful for monitoring tyrosine kinase inhibitor therapy in a patient receiving the drug to evaluate whether the patient will develop resistance to the drug. Furthermore, the assay methods of the present invention are useful for optimizing the dose of a tyrosine kinase inhibitor in a patient receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects.
摘要翻译：本发明提供了用于分析生物标志物组合以在诊断患有癌症的患者中个体化酪氨酸激酶抑制剂治疗的方法。具体而言，本发明的测定方法可用于预测，鉴定或监测肿瘤，肿瘤细胞或患者对酪氨酸激酶抑制剂治疗的应答，其使用基于生物标志物分析的算法。本发明的测定方法也可用于预测患者是否具有发生毒性或对酪氨酸激酶抑制剂治疗抗性的风险。此外，本发明的测定方法可用于监测接受药物的患者中的酪氨酸激酶抑制剂治疗，以评估患者是否会对药物产生耐药性。此外，本发明的测定方法可用于优化接受药物的患者中酪氨酸激酶抑制剂的剂量以实现治疗功效和/或减少毒副作用。

5. 发明申请

WO2005059160A2 IDENTIFICATION AND VERIFICATION OF METHYLATION MARKER SEQUENCES 审中-公开
标题翻译：甲基标记序列的鉴定和验证
公开(公告)号：WO2005059160A2
公开(公告)日：2005-06-30
申请号：PCT/US2004/042189
申请日：2004-12-15
申请人： BAYER HEALTHCARE LLC , BEARD, Chris , BURGESS, Chris , GANNON, Allison , HARVEY, Jeanne , LECHNER, John, F. , LI, Zheng
发明人： BEARD, Chris , BURGESS, Chris , GANNON, Allison , HARVEY, Jeanne , LECHNER, John, F. , LI, Zheng
IPC分类号： C12Q
CPC分类号： C12Q1/6886 , C12Q1/6809 , C12Q1/6827 , C12Q2600/112 , C12Q2600/136 , C12Q2600/154 , C12Q2523/125 , C12Q2565/501
摘要： The present invention relates to methods for identifying among the genes that are downregulated in cells or tissues having disease including cancer, the CpG sites within the CpG islands of said genes, wherein the identified CpG sites show great potential for diagnostic utility. In another aspect, the present invention also provides methods of using the selected CpG sites for purposes of diagnosis, prognosis, staging, assessing or monitoring the therapy of or recovery from a disease such as cancer.
摘要翻译：本发明涉及用于鉴定在具有疾病的细胞或组织中下调的基因的方法，所述基因在所述基因的CpG岛内的CpG位点，其中所鉴定的CpG位点具有很大的诊断效用潜力。另一方面，本发明还提供了使用所选择的CpG位点用于诊断，预后，分期，评估或监测疾病如癌症的治疗或恢复的方法。

6. 发明申请

WO2009079208A2 METHYLATION MARKERS FOR CANCER 审中-公开
标题翻译：癌症甲基标记物
公开(公告)号：WO2009079208A2
公开(公告)日：2009-06-25
申请号：PCT/US2008/085351
申请日：2008-12-03
申请人： SIEMENS HEALTHCARE DIAGNOSTICS INC. , HARVEY, Jeanne , MUNNES, Marc
发明人： HARVEY, Jeanne , MUNNES, Marc
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2523/125 , C12Q2600/112 , C12Q2600/154
摘要： The present invention is directed toward methods useful in the diagnosis of cancers such as colorectal cancer. Such methods can also be useful in determining the susceptibility to or the stage of cancer. The invention discloses CpG sites in the PERl, ZNF 145, and MN/CA6 genes that are differentially methylated in cancer. Generally, the inventive methods involve determining the extent of methylation at one or more differentially methylated CpG sites in a subject or a sample obtained from a subject and determining presence of, susceptibility to, and/or stage of cancer based on the extent of methylation at such CpG sites.
摘要翻译：本发明涉及可用于诊断癌症如结肠直肠癌的方法。这样的方法也可用于确定癌症的易感性或阶段。本发明公开了在癌症中差异甲基化的PER1，ZNF145和MN / CA6基因中的CpG位点。通常，本发明的方法包括确定受试者中的一个或多个差异甲基化CpG位点或从受试者获得的样品中的甲基化程度，并基于甲基化程度确定癌症的敏感性和/或癌症阶段的存在这样的CpG位点。

7. 发明申请

WO2009012140A3 DRUG SELECTION FOR LUNG CANCER THERAPY USING ANTIBODY-BASED ARRAYS 审中-公开
标题翻译：使用基于抗体的阵列进行肺癌治疗的药物选择
公开(公告)号：WO2009012140A3
公开(公告)日：2009-03-05
申请号：PCT/US2008069764
申请日：2008-07-11
申请人： PROMETHEUS LAB INC , SINGH SHARAT , HARVEY JEANNE
发明人： SINGH SHARAT , HARVEY JEANNE
IPC分类号： G01N33/574 , C12N5/08 , C12Q1/00
CPC分类号： G01N33/57423 , G01N33/5041 , G01N33/5044 , G01N33/5082 , G01N2500/10 , G01N2800/52
摘要： The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
摘要翻译：本发明提供了用于检测肿瘤细胞中信号转导途径组分的活化状态的组合物和方法。关于源自使用本发明的信号转导途径组分的活化状态的信息可用于癌症诊断，预后和癌症治疗的设计。

8. 发明申请

WO2008036802A3 ANTIBODY-BASED ARRAYS FOR DETECTING MULTIPLE SIGNAL TRANSDUCERS IN RARE CIRCULATING CELLS 审中-公开
标题翻译：用于检测罕见循环细胞中多个信号转导体的基于抗体的阵列
公开(公告)号：WO2008036802A3
公开(公告)日：2008-05-08
申请号：PCT/US2007079002
申请日：2007-09-20
申请人： PROMETHEUS LAB INC , HARVEY JEANNE , SINGH SHARAT , KIM PHILLIP , LIU XINJUN , BARHAM ROBERT , LIU LIMIN
发明人： HARVEY JEANNE , SINGH SHARAT , KIM PHILLIP , LIU XINJUN , BARHAM ROBERT , LIU LIMIN
IPC分类号： G01N33/543
CPC分类号： G01N33/57484 , G01N33/54306
摘要： The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.
摘要翻译：本发明提供用于检测稀有循环细胞中多个信号转导分子的活化状态和/或总量的基于抗体的阵列及其用于促进癌症预后和诊断以及个性化靶向治疗的设计的方法。

9. 发明申请

WO2008036802A2 ANTIBODY-BASED ARRAYS FOR DETECTING MULTIPLE SIGNAL TRANSDUCERS IN RARE CIRCULATING CELLS 审中-公开
标题翻译：用于检测稀有循环细胞中多个信号传感器的基于抗体的阵列
公开(公告)号：WO2008036802A2
公开(公告)日：2008-03-27
申请号：PCT/US2007/079002
申请日：2007-09-20
申请人： PROMETHEUS LABORATORIES INC. , HARVEY, Jeanne , SINGH, Sharat , KIM, Phillip , LIU, Xinjun , BARHAM, Robert , LIU, Limin
发明人： HARVEY, Jeanne , SINGH, Sharat , KIM, Phillip , LIU, Xinjun , BARHAM, Robert , LIU, Limin
IPC分类号： G01N33/50
CPC分类号： G01N33/57484 , G01N33/54306
摘要： The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.
摘要翻译：本发明提供了用于检测罕见循环细胞中多种信号转导分子的活化状态和/或总量的基于抗体的阵列及其用于促进癌症预后和诊断的方法以及个性化，有针对性的治疗设计。

10. 发明申请

WO2005059160A3 IDENTIFICATION AND VERIFICATION OF METHYLATION MARKER SEQUENCES 审中-公开
标题翻译：甲基标记序列的鉴定和验证
公开(公告)号：WO2005059160A3
公开(公告)日：2007-10-04
申请号：PCT/US2004042189
申请日：2004-12-15
申请人： BAYER HEALTHCARE LLC , BEARD CHRIS , BURGESS CHRIS , GANNON ALLISON , HARVEY JEANNE , LECHNER JOHN F , LI ZHENG
发明人： BEARD CHRIS , BURGESS CHRIS , GANNON ALLISON , HARVEY JEANNE , LECHNER JOHN F , LI ZHENG
IPC分类号： C12Q1/68 , C07H21/04 , C12P19/34 , C12Q20060101
CPC分类号： C12Q1/6886 , C12Q1/6809 , C12Q1/6827 , C12Q2600/112 , C12Q2600/136 , C12Q2600/154 , C12Q2523/125 , C12Q2565/501
摘要： The present invention relates to methods for identifying among the genes that are downregulated in cells or tissues having disease including cancer, the CpG sites within the CpG islands of said genes, wherein the identified CpG sites show great potential for diagnostic utility. In another aspect, the present invention also provides methods of using the selected CpG sites for purposes of diagnosis, prognosis, staging, assessing or monitoring the therapy of or recovery from a disease such as cancer.
摘要翻译：本发明涉及用于鉴定在具有疾病的细胞或组织中下调的基因的方法，所述基因在所述基因的CpG岛内的CpG位点，其中所鉴定的CpG位点具有很大的诊断效用潜力。另一方面，本发明还提供了使用所选择的CpG位点用于诊断，预后，分期，评估或监测疾病如癌症的治疗或恢复的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式